Evidence map›Paper›PMID 26339296›Full record

ArticleDiabetes management (London, England)

Diabetes prevention: global health policy and perspectives from the ground.

Michael Bergman, Martin Buysschaert, Peter Eh Schwarz, Ann Albright, Km Venkat Narayan, Derek Yach

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes management (London, England). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Michael BergmanNYU School of Medicine, Department of Medicine, Division of Endocrinology & Metabolism, 345 East 37th Street, Suite 313, New York, New York 10016, USA.
Martin BuysschaertUniversite Catholique de Louvain, Department of Endocrinology & Diabetology, University Clinic Saint-Luc, Brussels, Belgium.
Peter Eh SchwarzDepartment for Prevention & Care of Diabetes, Medical Clinic III, University Clinic Carl Gustav Carus, Technical University Dresden, Fetscherstr.74, 01307 Dresden, Germany.
Ann AlbrightDivision of Diabetes Translation, Centers for Disease Control & Prevention, 4770 Buford Highway NE, Atlanta, GA 30341, USA.
Km Venkat NarayanRollins School of Public Health, Emory University, Atlanta, GA, USA.
Derek YachGlobal Health & Agriculture Policy, PepsiCo 700 Anderson Hill Rd, Purchase, NY 10577, USA.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

Type 2 diabetes and other noncommunicable diseases are a growing public health challenge globally. An estimated 285 million people, corresponding to 6.4% of the world's adult population, has diabetes, which is expected to reach 552 million by the International Diabetes Federation in 2030. A much larger segment of the world's population, approximating 79 million individuals in the USA alone, has prediabetes. Globally, a relatively small percentage of those with diabetes or prediabetes are diagnosed with the potential for developing chronic complications. To address this epidemic, governments, in concert with the private sector, need to set policies that promote healthy nutritional and agricultural policies, favor modifications in the environment that encourage greater physical activity and make prevention affordable for all citizens at high risk. The public health sector has the charge of translating evidence-based findings into practical, accessible and cost-effective programs and monitoring the process to continuously improve prevention initiatives. The clinical sector has the formidable challenge of screening and identifying those at high risk and referring them to accredited intervention programs. There is a need to explore additional cost-effective interventions that are customized to meet individual needs that can be offered at the community and clinical levels. Thus, all three sectors, government, public health and clinical, each have a critical role in this process and by working in a partnership, ought to create the necessary synergies essential for making substantial forays in the prevention of Type 2 diabetes.

Identifiers

PMID26339296
PMCPMC4556601

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.